Finance News – Viking Therapeutics
What is your interest today?
Bitcoin
Crypto
Btc
Stocks
Shares
Tariffs
Stock
Investors
Ceo
Stock Market
Crypto Assets
Ethereum
Cryptocurrency
Price
Markets
Xrp
Eth
Etf
Bse
Ipo
Earnings
Investment
Stablecoin
Blockchain
Revenue
Solana
Index
Inflation
Sec
Trade
Interest Rates
Wall Street
Token
Sensex
Coinbase
Treasury
Federal Reserve
Nasdaq
Profit
Traders
Nse
China
Nifty
Sp 500
Bse Sensex
Investor
Gold
Tesla
Company
Economy
Nft Market
Series
Leisure Travel
Motilal Oswal Financial Services
Listing Criteria
Qsr
Internal Market
Stable
Legal Recourse
Individuals
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search finance news…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
CNBC Business • Aug 19, 2025
Viking Therapeutics shares fall 40% on disappointing obesity pill trial data
The company’s significant stock decline reflects investor concerns over its drug’s effectiveness, potentially strengthening the leading position of established competitors in the r...
Read Full Article →
Investopedia • Aug 19, 2025
Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results
The company experienced a significant decline in its market valuation following the release of data from a clinical trial evaluating its new oral medication aimed at reducing body...
Read Full Article →